Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carolyn Nancy Krasner, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377.
    Citations:    
  2. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229. PMID: 30765148.
    Citations:    
  3. Alimena S, Fiascone S, Krasner C, King M, Horowitz N. A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. Curr Probl Cancer. 2019 10; 43(5):443-449. PMID: 30770127.
    Citations:    
  4. Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):177-178. PMID: 27641482.
    Citations: 3     Fields:    Translation:Humans
  5. Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306. PMID: 27421044.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  6. Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol. 2016 Apr; 141(1):108-12. PMID: 27016236.
    Citations:    Fields:    Translation:Humans
  7. Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23. PMID: 26119093.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  8. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18. PMID: 25524310.
    Citations: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
  9. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9. PMID: 25254563.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  10. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. PMID: 24222211.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  11. Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25. PMID: 23975042.
    Citations:    Fields:    Translation:Humans
  12. Martin LP, Krasner C, Rutledge T, Ibañes ML, Fernández-García EM, Kahatt C, Gómez MS, McMeekin S. Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer. Med Oncol. 2013; 30(3):627. PMID: 23771800.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  13. del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol. 2013 Mar; 30(1):435. PMID: 23397080.
    Citations: 5     Fields:    Translation:Humans
  14. Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012 Oct; 127(1):161-7. PMID: 22765965.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  15. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6. PMID: 22750258.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  16. Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4. PMID: 22659193.
    Citations: 6     Fields:    Translation:Humans
  17. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct; 48(15):2361-8. PMID: 22541893.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  18. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33. PMID: 21833345.
    Citations: 8     
  19. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia F, Pujade-Lourraine E, Zintl P, Parekh TV, Poveda A. Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5046. PMID: 28023701.
    Citations:    
  20. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, Bradley CR, Birrer MJ, Matulonis U. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5004. PMID: 28023776.
    Citations:    
  21. Berek JS, Edwards RP, Parker L, DeMars LR, Herzog TJ, Lentz SS, Morris R, Akerley WL, Holloway RW, Method M, Plaxe SC, Walker JL, Schindler T, Schulze E, Krasner CN. Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. J Clin Oncol. 2011 May 20; 29(15_suppl):5048. PMID: 28023703.
    Citations:    
  22. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 01; 28(19):3107-14. PMID: 20516432.
    Citations: 78     Fields:    Translation:HumansCTClinical Trials
  23. Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8. PMID: 20405155.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  24. Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72. PMID: 19922985.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  25. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9. PMID: 19917843.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  26. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6. PMID: 19826113.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  27. Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009 Dec; 115(3):443-6. PMID: 19804902.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  28. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009 Jun; 123(6):1262-7.e1. PMID: 19501233.
    Citations: 12     Fields:    Translation:Humans
  29. Miller DS, Blessing JA, Krasner CN, Drake RD, Higgins R, McMeekin DS, Puneky LV. A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2009 May 20; 27(15_suppl):e16507. PMID: 27960769.
    Citations:    
  30. Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, Li J, Su Y, Dhawan R, Kaye S. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol. 2009 May 20; 27(15_suppl):5526. PMID: 27962478.
    Citations:    
  31. Krasner C, Duska L. Management of women with newly diagnosed ovarian cancer. Semin Oncol. 2009 Apr; 36(2):91-105. PMID: 19332244.
    Citations: 2     Fields:    Translation:Humans
  32. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 01; 27(16):2686-91. PMID: 19332726.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  33. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9. PMID: 19058838.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  34. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6. PMID: 19001330.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  35. Miller DS, Blessing JA, Krasner CN, Mannel RJ. A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group. J Clin Oncol. 2008 May 20; 26(15_suppl):5524. PMID: 27950846.
    Citations:    
  36. Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523. PMID: 27950841.
    Citations:    
  37. Krasner CN, Seiden MV, Penson RT, Roche M, Kendall DL, Young J, Matulonis UA, Pereira L, Berlin ST. NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5593. PMID: 27950463.
    Citations:    
  38. Matulonis UA, Berlin ST, Krasner CN, Tyburski K, Lee J, Roche M, Ivy SP, Lenahan C, King M, Penson RT. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5501. PMID: 27950813.
    Citations:    
  39. Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590. PMID: 27950420.
    Citations:    
  40. Kanwar VS, Heath J, Krasner CN, Pearce JM. Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy. Pediatr Blood Cancer. 2008 May; 50(5):1060-2. PMID: 17914739.
    Citations: 5     Fields:    Translation:Humans
  41. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24. PMID: 18000504.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  42. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903. PMID: 17245695.
    Citations: 42     Fields:    Translation:Humans
  43. Growdon WB, Lopez-Varela E, Littell R, Oliva E, Seiden M, Krasner C, Lee H, Fuller A. Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):262-8. PMID: 17587320.
    Citations: 5     Fields:    Translation:Humans
  44. Olawaiye A, Lee LM, Krasner C, Horowitz N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol. 2007 Sep; 106(3):628-30. PMID: 17561233.
    Citations: 4     Fields:    Translation:Humans
  45. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10). PMID: 17525937.
    Citations:    
  46. Krasner C. Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol. 2007 Aug-Sep; 106(1-5):76-80. PMID: 17826626.
    Citations: 8     Fields:    Translation:HumansAnimals
  47. Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80. PMID: 16806439.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  48. Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV. Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081. PMID: 27952385.
    Citations:    
  49. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020. PMID: 27952190.
    Citations:    
  50. Krasner CN, Seiden MV, Fuller AF, Roche M, Verrill CL, D'Amato F, Tretyakov O, Tyburski K, Matulonis UA, Supko JG. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5008. PMID: 27952185.
    Citations:    
  51. Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085. PMID: 27952379.
    Citations:    
  52. Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25. PMID: 16611953.
    Citations: 2     Fields:    Translation:Humans
  53. Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4. PMID: 16566993.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  54. Vaidya AP, Littell R, Krasner C, Duska LR. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer. 2006 Jan-Feb; 16 Suppl 1:267-72. PMID: 16515602.
    Citations: 4     Fields:    Translation:Humans
  55. Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005 Dec; 30(6):563-9. PMID: 16376743.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  56. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41. PMID: 16343179.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  57. Matulonis UA, Campos S, Krasner C, Duska L, Penson RP, Falke R, Roche M, Smith LM, Lee H, Seiden MV. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010. PMID: 27946271.
    Citations:    
  58. McMeekin DS, Krasner C, Chan S, Braly P, Kaye S, Provencher D, Trifan OC, Michiels B, Gore M. Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):5011. PMID: 27946277.
    Citations:    
  59. Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159. PMID: 27946709.
    Citations:    
  60. Krasner CN, Debernardo RL, Findley M, Penson R, Matulonis U, Atkinson T, Roche M, Seiden MV. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5063. PMID: 27946319.
    Citations:    
  61. DeBernardo RL, Perkins RB, Littell RD, Krasner CN, Duska LR. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol. 2005 May; 105(5 Pt 1):1006-11. PMID: 15863537.
    Citations: 2     Fields:    Translation:Humans
  62. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31. PMID: 15581974.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  63. Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151. PMID: 28016790.
    Citations:    
  64. Krasner CN, McMeekin S, Chan S, Braly P, Kaye S, Provencher D, Klecz J, Michiels B, Van de Velde H, Gore M. A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5045. PMID: 28015535.
    Citations:    
  65. Matulonis U, Krasner C, Atkinson T, Penson R. Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5148. PMID: 28016806.
    Citations:    
  66. Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7. PMID: 15196868.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  67. Schwaber MJ, Krasner CN, Gold HS, Venkataraman L, Avigan DE, Karchmer AW, Uhl L. Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures. J Clin Apher. 2003; 18(1):37-9. PMID: 12717792.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  68. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001 Dec; 2(4):341-9. PMID: 11762415.
    Citations: 6     Fields:    Translation:HumansAnimals
  69. Liu SK, Rassai H, Krasner C, Braun J, Matolo NM. Urinary catheter in laparoscopic cholecystectomy: is it necessary? Surg Laparosc Endosc Percutan Tech. 1999 Jun; 9(3):184-6. PMID: 10803996.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  70. Periyakoil V, Krasner C. Moraxella catarrhalis bacteremia as a cause of erythema nodosum. Clin Infect Dis. 1996 Sep; 23(3):650-1. PMID: 8879804.
    Citations:    Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Krasner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (196)
Explore
_
Co-Authors (56)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.